Member Info for Fadec92

Thanks BoilB it looks like they found a different way of inhibiting TYK2 achieving similar results in specificities and differentiation as BMS Deucravacitinib that’s the Pseudokinase Domain JH2 inhibitor with the recent good results and very high differentiation between the other JAKS 2/3, Sareum is a Catalytic Domain JH1!

Bristol Myers Squibb Deucravacitinib (BMS-986165)

https://imgur.com/a/rFZ1rq3

Somebody in the US is buying

£65k is an XOFF off exchange from the OTC!

https://twitter.com/fadec92/status/1358867472259121154?s=21

There’s also then the idea of frac sand if this can be sold as it is the by product of the processing tech, the customer base being at the edge of the Uinta Basin, also this region has a frack sand company at the north of Vernal, so any info of testing of sand once a location has been accepted and RNS than everyone can update the economics too a much larger figure!

The Feed is based on PetroTeq’s operations, just scaled up too run 10k so there looks to be a plant in this area, and the PetroTeq’s plant and the FEED design has the attributes that the items are available to buy, ie no specialist design so I would have thought the items can be repurposed to achieve a better build time and used to build the 10k plant, but until they say this then that question cannot be fully answered!

There’s potentially a land position in Vernal that has the right attributes so let see!

Eli Lilly has an option on the Esperas Chk1 in phase trials in Canada, originally Eli Lilly compound!

https://scrip.pharmaintelligence.informa.com/deals/201520181

I think the problem for a potential suitor invester would be that there is no human data and the amount of risk under the shawdows of big pharma companies that do have v.good data in a lot of indications that have proof of best in class, it’s not good enough to say best in class how many companies in aim say that and turn out not to be, there’s no definitive indication in autoimmune other than covid which is good and promising but opportunistic and was an opportunity that fell into their laps as I think Tim actually said that in the last interview!

I think some in human data is needed and would follow TLL Pharmaceutical’s TLL018 which is in phase trials with highly differentiated JAK1/TYK2 vs JAK2/3!

Ahfam yes tofa is Xeljanz in the article but they also have other Tyk2/JAK1 in phase trials without warnings!

Isn’t that just Tofa though I’m not aware of black box warnings for the pipeline class, but not fully researched that yet!

Why would Pfizer be interested? They have a range of Tyk2/JAK inhibitors in the pipeline in phase trials?

https://imgur.com/a/ZJU1ZDL

The last drop was too 1.47p on the FLT3 news!

I’m not going too stop posting facts guys no matter even if your rude, but it shouldn’t really effect you this badly and a reasonable discussion is always better!

It’s a valid point Belhus why would Merck be interested if it has a few ATR inhibitors that have some good data and recognition?

Merck have got their ATR inhibitors, 3 off which and are upstream of CHK1 they are very similar so don’t know about that!

https://www.pnas.org/content/116/27/13374

https://www.merckgroup.com/en/research/healthcare-pipeline.html

Or sell the sand for the unconventional completions ie fracking, I guess the suitable spot for TomCo’s operations will also have the sand tested as PetroTeq has done, frac sand sells at a premium like marine grade low sulphur shipping/heating fuel oil does, if you also look where the operations are they are right where the Uintah oil and gas Basin resides so customer base is close!

VLSFO Fuel prices per barrel!

https://twitter.com/fadec92/status/1352356539798069250?s=21

https://petroteq.energy/news/press-releases/detail/369/petroteq-energy-announces-that-testing-of-the-sand-tailings

The Pfizer CEO Albert Bourla has said that he’s progressing the portfolio based on Different JAK/Tyk2 on indications so in effect saying that there’s not a molecule too suit a broad base of indications, so that’s what I think too, i would be more reassured too know what indication Tim and John have based on the data not just covid, and I’m sure other companys would like too know this too!

Don’t think you can be best in class in all indications, different selectivitys define an indication is what I’m reading!

https://imgur.com/a/GXx1TUj

https://imgur.com/a/YtG9Y8V

SAGD is what the big companies in Alberta Canada used and has a EROEI of 4:1

So you can see the big difference and why people are excited over PetroTeq’s CORT technology, with 22:1 EROEI, plus the clean sand and an closed loop system so 99% efficient is definitely a big deal!

Oil SAGD operations!

https://www.oilsandsmagazine.com/projects/thermal-in-situ

Darientaylor

The EROEI (Energy Return Over Energy Invested) is a very high category!

PetroTeq have in place a CPR by consultant Chapman Petroleum Engineering, and as a result of the extensive analysis is the effect of all combined energy saving features returned a calculated figure below :-

22:1 EROEI

Here’s the evidence!

https://imgur.com/a/F7lrWYP

I think when the video of the operations and PR is in place it will hit home, this is a big first step, the profit per barrel is in the highest category for a low investment scenario, low capex high return, and not the typical risks associated with the production of oil and gas, and then the sand in and around the Uinta Basin that has a shortage of sand for the unconventional!

Continuous Production is the key, keep producing and there will be a lot of eyes on this operation from bigger companies looking too lease land around Uinta Basis oil sands as the economic’s of the plant has the best margins possible and a greener way with clean sand the by product, also as oil prices increase the unconventional drilling and the selling of sand too, investment opportunities right here!